1)厚生労働省:糖尿病性腎症重症化予防プログラムの改定について.令和6年3月28日 https://www.mhlw.go.jp/stf/newpage_38699.html(2024年7月9日閲覧)
2)友利幸之介,他:スコーピングレビューのための報告ガイドライン日本語版:PRISMA-ScR.日臨作療研 7: 70-76, 2020
3)Ouzzani M, et al: Rayyan-a web and mobile app for systematic reviews. Syst Rev 5: 210, 2016
4)Kazawa K, et al: Development and Evaluation of Disease Management Program and Service Framework for Patients with Chronic Disease. Health 7: 729-740, 2015
5)Kawaguchi H, et al: Does disease management for diabetic nephropathy reduce medical expenditure? Evidence from a three-period difference-in-differences analysis. BMC Health Serv Res 20: 403, 2020
6)Ikeda A, et al: Effect of the Diabetic Nephropathy Aggravation Prevention Program on medical visit behavior in individuals under the municipal national health insurance. J Diabetes Investig 14: 782-791, 2023
7)Kazawa K, et al: Efficacy of a disease management program focused on acquisition of self-management skills in pre-dialysis patients with diabetic nephropathy: 24 months follow-up. J Nephrol 28: 329-338, 2015
8)Watanabe H, et al: Long-term effectiveness of a disease management program to prevent diabetic nephropathy: a propensity score matching analysis using administrative data in Japan. BMC Endocr Disord 22: 135, 2022
9)天野方一,他:千葉県市原圏域における糖尿病性腎症重症化予防事業の実施報告.帝京医誌 45: 45-52, 2022
10)天野方一,他:東京都国保・自治体における糖尿病性腎症重症化予防プログラムの実施状況.帝京医誌 44: 153-163, 2021
11)Matsushita K, et al: Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int 90: 1109-1114, 2016